Ethics of newborn screening

Current Paediatrics

Volumn 16, Issue 3, 2006, Pages 216-220

  Stewart, Fiona ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Genetic; Guthrie; Metabolic; Newborn; Screening

Indexed keywords

ARTICLE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ETHICS; FABRY DISEASE; GENETIC PROCEDURES; HEALTH CARE; HEALTH PROGRAM; HEALTH SERVICE; HETEROZYGOTE DETECTION; HUMAN; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 33744537524     PISSN: 09575839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cupe.2006.03.002     Document Type: Article

References (19)

1. Folling A. Uber ausscheidung von phenylbrenztraubensaure in den harn als stoffwechselanomalie in verbindung mit imbezillitat. Hoppe Seylers Z Physiol Chem 277 (1934) 169-179 [in German]
2. Guthrie R., and Susi A. A simple phenyl alanin method for detecting phenylketonuria in large populations of new born infants. Pediatrics 32 (1963) 338-343
3. http://www.nsc.nhs.uk/whatscreening/whatscreen_ind.htm
4. Wilson J.M.G., and Jungner G. Principles and practice of screening for disease. Public Health Paper Number 34 (1968), World Health Organization, Geneva
5. Millington D.S., Kodo N., Terada N., Roe D., and Chace D.H. Analysis of diagnostic markers of genetic disorders in human blood and urine using tandem mass spectrometry with liquid secondary ion mass spectrometry. Int J Mass Spectr Ion Process 111 (1991) 21-28
6. Chace D., and Naylor E. Expansion of newborn screening programmes using automated tandem mass spectrometry. Mental Retardat Disabil Res Rev 5 (1999) 1504
7. Koeberl D.D., Millington D.S., Smith W.E., Weavil S.D., Muenzer J., McCandless S.E., et al. Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 26 (2003) 25-35
8. Wiley V., Carpenter K., Bayliss U., and Wilcken B. Newborn screening-is it really that simple?. Southeast Asian J Trop Med Public Health 34 Suppl. 3 (2003) 107-110
9. Wang D., Eadala B., Sadilek M., Chamoles N., Turecek F., Scott C.R., et al. Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin Chem 51 (2005) 898-900
10. Meikle P.J., Ranieri E., Simonsen H., Rozaklis T., Ramsay S.L., Whitfield P.D., et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 114 (2004) 909-916
11. Ramsay S.L., Meikle P.J., Hopwood J.J., and Clements P.R. Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides. Annal biochem 345 (2005) 30-46
12. Canadian Coordinating Office fo Health Technology Assessment. Laronidase CEDAC final recommendations and reasons for recommendation (2005), CCOHTA, Ottawa
13. McCAbe, Claxton K., and Tschuiya A. Orphan drugs and the NHS: should we value rarity?. Br Med J 331 (2005) 1016-1019 and related articles
14. Sims E.J., Mccormick J., Mehta G., and Mehta A. Steering committee of the UK cystic fibrosis database. J Pediatr 147 3 Suppl. (2005) S42-S46
15. Clarke A. The genetic testing of children. Oxford: BIOS; 1998.
16. Applying Public Health Strategies to Primary Immunodeficiency Diseases. A potential approach to genetic disorders. CDC MMWR Recommendations and Reports, January 2004, 53(RR01). p. 1-29, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5301a1.htm
17. Kerruish N.J., and Robertson S.P. Newborn screening: new developments, new dilemmas. J Med Ethics 31 (2005) 393-398
18. Our inheritance, our future, realising the potential of genetics in the NHS. HMSO June 2003.
19. Profiling the newborn: a prospective gene technology?' A report from a Joint Working Group of the Human Genetics Commission and the UK National Screening Committee March 2005-12-03. www.hgc.gov.uk